Objectives: To test CIDP patients for IgG positivity towards CV2.
Patients:
| NUMBER | CODE |
|---|---|
| 1 | 18-502 |
| 2 | 18-503 |
| 3 | 18-504 |
| 4 | 18-505 |
| 5 | 18-506 |
| 6 | 18-507 |
| 7 | 18-508 |
| 8 | 18-509 |
| 9 | 18-510 |
| 10 | 18-511 |
| 11 | 18-512 |
| 12 | 18-513 |
| 13 | 18-514 |
| 14 | 18-515 |
| 15 | 18-516 |
| 16 | 18-517 |
| 17 | 18-518 |
| 18 | 18-519 |
| 19 | 18-520 |
| 20 | 18-521 |
| 21 | 18-522 |
| 22 | 18-523 |
| 23 | 18-524 |
| 24 | 18-525 |
| 25 | 18-526 |
| 26 | 18-527 |
| 27 | 18-528 |
| 28 | 18-529 |
| 29 | 18-530 |
| 30 | 18-531 |
| 31 | 18-532 |
| 32 | 18-533 |
| 33 | 18-534 |
| 34 | 18-535 |
| 35 | 18-536 |
| 36 | 18-537 |
| 37 | 18-538 |
| 38 | 18-539 |
| 39 | 18-540 |
| 40 | 18-541 |
| 41 | 18-542 |
| 42 | 18-543 |
| 43 | 18-544 |
| 44 | 18-545 |
| 45 | 18-546 |
| 46 | 18-547 |
| 47 | 18-548 |
| 48 | CTRL- |
| 49 | 18-549 |
| 50 | 18-550 |
| 51 | 18-551 |
| 52 | 18-552 |
| 53 | 18-553 |
| 54 | 18-554 |
| 55 | 18-555 |
| 56 | 18-556 |
| 57 | 18-557 |
| 58 | 18-558 |
| 59 | 18-559 |
| 60 | 18-560 |
| 61 | 18-561 |
| 62 | 18-562 |
| 63 | 18-563 |
| 64 | 18-564 |
| 65 | 18-565 |
| 66 | 18-566 |
| 67 | 18-567 |
| 68 | 18-568 |
| 69 | 18-569 |
| 70 | 18-570 |
| 71 | 18-571 |
| 72 | 18-572 |
| 73 | 18-573 |
| 74 | 18-574 |
| 75 | 18-575 |
| 76 | 18-576 |
| 77 | 18-577 |
| 78 | 18-578 |
| 79 | 18-579 |
| 80 | 18-580 |
| 81 | CTRL- |
NF140 ICC:
- HEKs 293 Cells Transfection: 2018.02.07
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 for IgG with 5% goat serum in PBS.
- Secondary antibody: GAH 594 IgG (1/1000).
- Vectashield mounting medium.
Results: Sample 42 (18-543) were positive, the other samples were negative.
